216 related articles for article (PubMed ID: 20207845)
1. Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab.
Sloand EM; Olnes MJ; Weinstein B; Wu C; Maciejewski J; Scheinberg P; Young NS
Haematologica; 2010 Mar; 95(3):382-7. PubMed ID: 20207845
[TBL] [Abstract][Full Text] [Related]
2. Brief communication: Successful treatment of pure red-cell aplasia with an anti-interleukin-2 receptor antibody (daclizumab).
Sloand EM; Scheinberg P; Maciejewski J; Young NS
Ann Intern Med; 2006 Feb; 144(3):181-5. PubMed ID: 16461962
[TBL] [Abstract][Full Text] [Related]
3. Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia.
Maciejewski JP; Sloand EM; Nunez O; Boss C; Young NS
Blood; 2003 Nov; 102(10):3584-6. PubMed ID: 12881307
[TBL] [Abstract][Full Text] [Related]
4. [Clinical study of ciclosporin in patients with aplastic anemia and pure red-cell aplasia].
Kitamura K; Urabe A; Nomura T; Mizoguchi H; Takaku F
Rinsho Ketsueki; 1995 Mar; 36(3):175-84. PubMed ID: 7783321
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporine restores hematopoietic function by compensating for decreased Tregs in patients with pure red cell aplasia and acquired aplastic anemia.
Dao AT; Yamazaki H; Takamatsu H; Sugimori C; Katagiri T; Maruyama H; Zaimoku Y; Maruyama K; Ly TQ; Espinoza L; Nakao S
Ann Hematol; 2016 Apr; 95(5):771-81. PubMed ID: 26968551
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA.
Risitano AM; Selleri C; Serio B; Torelli GF; Kulagin A; Maury S; Halter J; Gupta V; Bacigalupo A; Sociè G; Tichelli A; Schrezenmeier H; Marsh J; Passweg J; Rotoli B;
Br J Haematol; 2010 Mar; 148(5):791-6. PubMed ID: 19995389
[TBL] [Abstract][Full Text] [Related]
7. Aplastic anemia and pure red cell aplasia associated with large granular lymphocyte leukemia.
Go RS; Lust JA; Phyliky RL
Semin Hematol; 2003 Jul; 40(3):196-200. PubMed ID: 12876668
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy: a final report of the nationwide cohort study in 2004/2006 by the Japan PRCA collaborative study group.
Hirokawa M; Sawada K; Fujishima N; Teramura M; Bessho M; Dan K; Tsurumi H; Nakao S; Urabe A; Fujisawa S; Yonemura Y; Kawano F; Oshimi K; Sugimoto K; Matsuda A; Karasawa M; Arai A; Komatsu N; Harigae H; Omine M; Ozawa K; Kurokawa M;
Br J Haematol; 2015 Jun; 169(6):879-86. PubMed ID: 25807974
[TBL] [Abstract][Full Text] [Related]
9. Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group.
Hirokawa M; Sawada K; Fujishima N; Nakao S; Urabe A; Dan K; Fujisawa S; Yonemura Y; Kawano F; Omine M; Ozawa K;
Haematologica; 2008 Jan; 93(1):27-33. PubMed ID: 18166782
[TBL] [Abstract][Full Text] [Related]
10. [The problem of acquired aplastic anaemia].
Solignac M;
Presse Med; 2003 Sep; 32(29):1378-80. PubMed ID: 14534504
[TBL] [Abstract][Full Text] [Related]
11. Treatment of pure red-cell aplasia and aplastic anaemia with ciclosporin: long-term clinical effects.
Tötterman TH; Höglund M; Bengtsson M; Simonsson B; Almqvist D; Killander A
Eur J Haematol; 1989 Feb; 42(2):126-33. PubMed ID: 2492947
[TBL] [Abstract][Full Text] [Related]
12. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
Waldmann TA
J Clin Immunol; 2007 Jan; 27(1):1-18. PubMed ID: 17216565
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of pure red cell aplasia with a single dose of rituximab in a child after major ABO incompatible peripheral blood allogeneic stem cell transplantation for acquired aplastic anemia.
Maschan AA; Skorobogatova EV; Balashov DN; Pashanov ED; Trakhtman PE; Schipitzina IP; Skvortsova YV; Rumiantzev AG
Bone Marrow Transplant; 2002 Sep; 30(6):405-7. PubMed ID: 12235527
[TBL] [Abstract][Full Text] [Related]
14. Antibody-mediated pure red-cell aplasia (PRCA): the Spanish experience.
Carracedo J; Madueño JA; Ramirez R; Martin-Malo A; de Francisco AL; Aljama P;
J Nephrol; 2005; 18(4):382-7. PubMed ID: 16245241
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia.
Helbig G; Stella-Holowiecka B; Krawczyk-Kulis M; Wojnar J; Markiewicz M; Wojciechowska-Sadus M; Kopera M; Kruzel T; Najda J; Nowak K; Holowiecki J
Haematologica; 2005 Nov; 90 Suppl():ECR33. PubMed ID: 16266924
[TBL] [Abstract][Full Text] [Related]
16. A pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome.
Kim H; Min YJ; Baek JH; Shin SJ; Lee EH; Noh EK; Kim MY; Park JH
Leuk Res; 2009 Feb; 33(2):222-31. PubMed ID: 18790532
[TBL] [Abstract][Full Text] [Related]
17. Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group.
Fujishima N; Sawada K; Hirokawa M; Oshimi K; Sugimoto K; Matsuda A; Teramura M; Karasawa M; Arai A; Yonemura Y; Nakao S; Urabe A; Omine M; Ozawa K;
Haematologica; 2008 Oct; 93(10):1555-9. PubMed ID: 18641028
[TBL] [Abstract][Full Text] [Related]
18. Acquired pure red cell aplasia: updated review of treatment.
Sawada K; Fujishima N; Hirokawa M
Br J Haematol; 2008 Aug; 142(4):505-14. PubMed ID: 18510682
[TBL] [Abstract][Full Text] [Related]
19. Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation.
Zhu KE; Li JP; Zhang T; Zhong J; Chen J
Hematology; 2007 Apr; 12(2):117-21. PubMed ID: 17454192
[TBL] [Abstract][Full Text] [Related]
20. Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.
Rzepecki P; Sarosiek T; Szczylik C
Jpn J Clin Oncol; 2006 Jan; 36(1):46-9. PubMed ID: 16423840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
